Gene-drug interactions (data source: DGIdb)
Gene Name Entrez ID Drug Name Chembl ID Interaction Types Sources publications

Variant-drug associations (data source: PharmGKB)
Gene Name Variant Alleles Chemical Phenotype Category Significance Notes Sentence Publications Annotation ID
HLA-G rs371194629 del/del methotrexate no Patients were defined as responders based on a 28-joint Disease Activity Score (DAS28) of less than 3.2, or non-responders if DAS28 was greater than 3.2. Variant described as "HLA-G -/- 14 bp polymorphism". Genotype del/del is not associated with increased response to methotrexate in people with Arthritis, Rheumatoid. 19088262 1451159740
HLA-G rs371194629 del/del methotrexate efficacy yes Responders = DAS reduction from baseline values ranged from >0.6 to >1.2. If DAS decrease proved to be ≤0.6, the patients were considered as nonresponders. Variant described as HLA-G 14-bp with association for −14/−14 bp genotype. Genotype del/del is associated with increased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotypes ATTTGTTCATGCCT/ATTTGTTCATGCCT + ATTTGTTCATGCCT/del. 16906016 1451159760
HLA-G rs17179108 CT capecitabine efficacy yes The authors examined disease free survival (DFS) as well as overall survival (OS). The CT genotype was associated with improved DFS, but not OS. Genotype CT is associated with increased response to capecitabine or fluorouracil in people with Colorectal Neoplasms as compared to genotype CC. 26633805 1447678780
HLA-G rs9380142 GG capecitabine efficacy yes The authors examined disease free survival (DFS) as well as overall survival (OS). The GG genotype was associated with decreased DFS and OS. Genotype GG is associated with decreased response to capecitabine or fluorouracil in people with Colorectal Neoplasms as compared to genotypes AA + AG. 26633805 1447678879
HLA-G rs1610696 CG + GG capecitabine efficacy no The authors examined disease free survival (DFS) as well as overall survival (OS). Neither were significantly associated with any genotype. Genotypes CG + GG are not associated with response to capecitabine or fluorouracil in people with Colorectal Neoplasms as compared to genotype CC. 26633805 1447678763
HLA-G rs371194629 ATTTGTTCATGCCT/ATTTGTTCATGCCT + ATTTGTTCATGCCT/del capecitabine efficacy yes The authors examined disease free survival (DFS) as well as overall survival (OS). The ins/del + ins/ins genotypes were associated with improved DFS, but not OS. Genotypes ATTTGTTCATGCCT/ATTTGTTCATGCCT + ATTTGTTCATGCCT/del is associated with increased response to capecitabine or fluorouracil in people with Colorectal Neoplasms as compared to genotype del/del. 26633805 1447678770
HLA-G rs1710 GG capecitabine efficacy no The authors examined disease free survival (DFS) as well as overall survival (OS). Neither were significantly associated with any genotype. Genotype GG is not associated with response to capecitabine or fluorouracil in people with Colorectal Neoplasms as compared to genotypes CC + CG. 26633805 1447678633
HLA-G rs1063320 CC capecitabine efficacy no The authors examined disease free survival (DFS) as well as overall survival (OS). Neither were significantly associated with any genotype. Genotype CC is not associated with response to capecitabine or fluorouracil in people with Colorectal Neoplasms as compared to genotypes CG + GG. 26633805 1447678756
HLA-G rs17179101 AC capecitabine efficacy no The authors examined disease free survival (DFS) as well as overall survival (OS). Neither were significantly associated with any genotype. Genotype AC is not associated with response to capecitabine or fluorouracil in people with Colorectal Neoplasms as compared to genotype CC. 26633805 1447678642
HLA-G rs1707 CC capecitabine efficacy no The authors examined disease free survival (DFS) as well as overall survival (OS). Neither were significantly associated with any genotype. Genotype CC is not associated with response to capecitabine or fluorouracil in people with Colorectal Neoplasms as compared to genotypes CT + TT. 26633805 1447678621